The remarkable clinical success of immune-checkpoint inhibitors for the treatment of a
growing number of cancer types has sparked interest in the discovery of novel forms of …

Monoclonal antibody (mAb) therapy has successfully been introduced as treatment of
several lymphomas and leukemias. However, solid tumors reduce the efficacy of mAb …

Cytokines have long been used for therapeutic applications in cancer patients. Substantial
side effects and unfavorable pharmacokinetics limit their application and may prevent dose …

Antibody-cytokine fusion proteins represent a novel class of biopharmaceuticals, with the
potential to increase the therapeutic index of cytokine 'payloads' and to promote leukocyte …

Since the FDA approval of the first therapeutic antibody 35 years ago, antibody-based
products have gained prominence in the pharmaceutical market. Building on the early …

Cytokine-based therapeutics have been shown to mediate objective responses in certain
tumor entities but suffer from insufficient selectivity, causing limiting toxicity which prevents …

The advent of biologic therapies, particularly antibody therapeutics, has revolutionized the
pharmacological treatment of many rheumatic diseases. Antibody discovery began with the …

We describe the cloning and characterization of a novel fusion protein (termed L19‐mIL12),
consisting of murine interleukin‐12 in single‐chain format, sequentially fused to the L19 …

Systemic toxicities have severely limited the clinical application of tumor necrosis factor
(TNF) as an anticancer agent. Activity‐on‐Target cytokines (AcTakines) are a novel class of …

Cytokine signaling is critical to a range of biological processes including cell development,
tissue repair, aging, and immunity. In addition to acting as key signal mediators of the …